Aprindine

Oral
Supraventricular arrhythmias, Ventricular arrhythmias

Advanced heart failure, severe conduction disturbances, parkinsonism, convulsive disorders.

Bradycardia, hypotension, hepatic or renal impairment. Perform blood and LFT during therapy.

Tremor, vertigo, ataxia, diplopia, memory impairment, hallucinations, convulsions; nausea, vomiting, bloating, hepatitis, cholestatic jaundice.
Potentially Fatal: Agranulocytosis.

Amiodarone.

Description:
Mechanism of Action: Aprindine is a class Ib antiarrhythmic agent which directly interferes with depolarisation of the cell membrane by blocking the fast inward current of Na into cardiac cells. It has a limited effect on the rate of change of the depolarisation phase of the action potential, shortens the repolarisation phase and the QT interval and elevates the fibrillation threshold.
Pharmacokinetics:
Absorption: Readily absorbed from the GI tract.
Distribution: 85-95% bound to plasma proteins.
Excretion: Excreted in the urine and bile. Half-life: about 20-27 hr.

Cardiac Drugs